Chengdu Pukang Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B1

  • Investors
  • 8

Chengdu Pukang General Information

Description

Developer of polypeptide-modified side chains and single-molecule PEG derivatives designated for drug delivery and improving drug stability. The company has built a polypeptide long-acting modifier platform that can provide different types of peptide long-acting side chain molecules, high-quality long-acting side chain design services, quality research, and CDE documents, its products include fatty alkane series, MIPA series and cholesterol series products, enabling its customers to quickly realize the molecular screening and evaluation of innovative peptide drugs.

Contact Information

Website
www.pu-kang.com
Formerly Known As
Chengdu Pukang Weixin Biotechnology Co., Ltd., Chengdu Pusaiweixin Biotechnology Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 1-9,Building7, No.288 of North Rongtai Avenue
  • WenJiang District
  • Chengdu, Sichuan 611137
  • China
+86 028
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Room 1-9,Building7, No.288 of North Rongtai Avenue
  • WenJiang District
  • Chengdu, Sichuan 611137
  • China
+86 028

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chengdu Pukang Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B1) 06-Jun-2024 Completed Generating Revenue
2. Later Stage VC (Series B) 31-Oct-2023 Completed Generating Revenue
1. Later Stage VC 23-Jul-2021 Completed Generating Revenue
To view Chengdu Pukang’s complete valuation and funding history, request access »

Chengdu Pukang Patents

  • 1

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 1

    Pending

  • Expiring in next 12 mo

Chengdu Pukang Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026149017-A1 Pseudopeptide compound, and preparation method therefor and use thereof Pending 13-Jan-2025

Chengdu Pukang Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
HM Capital Venture Capital Minority
IDG Capital Venture Capital Minority
Mirae Asset Global Investments (Asset Management) Asset Manager Minority
Nanjing Xingong Emerging Industry Investment Management Growth/Expansion Minority
GL Ventures Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

Chengdu Pukang FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process